Why the study?
Right ventricular infarction is a complication of inferior STEMI, but its clinical outcomes in the contemporary primary PCI era needed investigation.
Does right ventricular infarction worsen clinical outcomes in patients with inferior STEMI?
Does right ventricular infarction worsen clinical outcomes in patients with inferior STEMI?
In patients with inferior STEMI, the presence of right ventricular infarction is associated with higher in-hospital mortality but similar mid-term major adverse cardiac events compared to those without right ventricular infarction.
Answers are grounded in this paper and cite their sources.
RVI in inferior STEMI links to higher in-hospital mortality despite primary PCI; leaves open whether targeted strategies alter mid-term MACE.
Right ventricular infarction (RVI) is a complication following inferior ST-elevation myocardial infarction (STEMI). The aim of the present study was to investigate the clinical outcomes of RVI in the contemporary primary percutaneous coronary intervention (PCI) era. The primary endpoint was in-hospital death, and the secondary endpoint was major adverse cardiac events (MACE), defined as the composite of cardiovascular death, re-hospitalization for heart failure, and non-fatal acute myocardial infarction (AMI). Event-free survival curves for MACE were constructed using the Kaplan-Meier method, and statistical differences between curves were assessed using the log-lank test. A total of 1354 patients with AMI were screened from January 2010 to December 2016. The final study population involved 315 patients with STEMI whose infarct related artery (IRA) was the right coronary artery (RCA). We categorized these 315 patients into the RVI group (n = 85) and the non-RVI group (n = 230). Median follow-up duration was 358 (IQR: 208-987) days. In-hospital deaths were more frequently observed in the RVI group (9.4%) than in the non-RVI group (3.0%) (P = 0.018). However, the incidence of MACE was not different between the groups (P = 0.537). In conclusion, in-hospital clinical outcomes were poorer in the RVI group than in the non-RVI group. However, mid-term MACE was not different between the two groups, suggesting the importance of aggressive acute treatment for STEMI patients with RVI.
No takes yet. Share an insight, caveat, or question.
Noguchi et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: